Back to Results

LianBio ADR (LIANY)

LianBio ADR is a depositary receipt listed on OTC Markets that represents the common stock of LianBio. The underlying issuer is a biotechnology company focused on developing medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications in China and other Asian countries. Its pipeline includes mavacamten for obstructive hypertrophic cardiomyopathy, which is in the Phase 3 EXPLORER-CN trial; TP-03 for Demodex blepharitis and meibomian gland disease, which is in the Phase 3 LIBRA trial; NBTXR3 for head and neck squamous cell carcinoma and other solid tumors; Infigratinib for FGFR2 gene amplification; and BBP-398 for solid tumors. LianBio was incorporated in 2019 and is headquartered in Princeton, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-LIAN.Y
—
—
—
—
—
—
Excellent
—
—
0.38
0.0%
August 18, 2026
—
—
—
8.653 M
—
—
—
—
—
—
Send a message
Valuation • Fair Value

LianBio ADR (OTC-LIAN.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for LianBio ADR (OTC-LIAN.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

Not available

Data is currently unavailable.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for LianBio ADR (OTC-LIAN.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for LianBio ADR (OTC-LIAN.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

Not available

Data is currently unavailable.

EBITDA

0 K

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review LianBio ADR (OTC-LIAN.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for LianBio ADR (OTC-LIAN.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Excellent

Positive financial-health read.

Piotroski Score

Not available

Data is currently unavailable.

Beneish M-Score

Not available

Data is currently unavailable.

Altman Z-Score

Not available

Data is currently unavailable.

FCF / Net Income

Not available

Data is currently unavailable.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for LianBio ADR (OTC-LIAN.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for LianBio ADR (OTC-LIAN.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 18, 2026

Days to Earnings

28

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

0.38

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for LianBio ADR (OTC-LIAN.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

LianBio ADR (OTC-LIAN.Y) Stock Forecast & Technical Outlook

Review LianBio ADR (OTC-LIAN.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for LianBio ADR (OTC-LIAN.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for LianBio ADR (OTC-LIAN.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, LianBio ADR (OTC-LIAN.Y) has a Hold consensus, with 0 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 1
Sell 0
FAQ • Fast Investor Answers

LianBio ADR (OTC-LIAN.Y) Stock FAQ

Quick answers about LianBio ADR (OTC-LIAN.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
Not available
Data is currently unavailable
Valuation Rating
Not available
Classification is not available
Analyst Target
Not available
Data is currently unavailable
Financial Health
Excellent
Current financial-health read

A fair value estimate for LianBio ADR (OTC-LIAN.Y) is not currently available in the latest data file.

A clear undervalued or overvalued classification is not currently available in the latest data file.

An analyst price target for LianBio ADR (OTC-LIAN.Y) is not currently available in the latest data file.

The current financial health read for LianBio ADR (OTC-LIAN.Y) is Excellent. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for LianBio ADR (OTC-LIAN.Y) is August 18, 2026.

Based on the current data, dividend yield is 0.0%, upcoming dividend amount is 0.38.

The current market capitalization listed for LianBio ADR is 8.653 M.

The ticker symbol for LianBio ADR is OTC-LIAN.Y, and the stock is listed on OTC Markets.

LianBio ADR (OTC-LIAN.Y) is listed on OTC Markets.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Nuo Therapeutics Inc (AURX) Nuo Therapeutics Inc (AURX)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)